Case Example of Dose Optimization Using Data From Bortezomib Dose-Finding Clinical Trials [Statistical Analysis]
Conclusions
When considering the entire course of treatment, the approved bortezomib dose exceeds the conventional ceiling DLT rate of 20% to 33%. Retrospective analysis of trial data provides an opportunity for dose optimization of MTAs. Future dose-finding studies of MTAs should take into account late-onset toxicities to ensure that a tolerable dose is identified for future efficacy and comparative trials.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Lee, Backenroth, Cheung, Hershman, Vulih, Anderson, Ivy, Minasian Tags: Clinical Trials, Phase I and Clinical Pharmacology, Statistics in Oncology Statistical Analysis Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Chemotherapy | Clinical Trials | Drugs & Pharmacology | Medical Training Application Service | Statistics | Study | Toxicology | Velcade